Skip to main content

Bionano Genomics Inc

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

BNGO$1.16+0.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Bionano Genomics, Inc.
Date: March 5, 2024By:/s/ R. Erik Holmlin, Ph.D.
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of R. Erik Holmlin, Ph.D. and Gülsen Kama as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Bionano Genomics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ R. Erik Holmlin, Ph.D.Chief Executive Officer and Director (Principal Executive Officer)March 5, 2024
R. Erik Holmlin, Ph.D.
/s/ Gülsen KamaChief Financial Officer(Principal Financial and Accounting Officer)March 5, 2024
Gülsen Kama
/s/ David L. Barker, Ph.D.DirectorMarch 5, 2024
David L. Barker, Ph.D.
/s/ Albert A. Luderer, Ph.D.DirectorMarch 5, 2024
Albert A. Luderer, Ph.D.
/s/ Yvonne Linney, Ph.D.DirectorMarch 5, 2024
Yvonne Linney, Ph.D.
/s/ Hannah MamuszkaDirectorMarch 5, 2024
Hannah Mamuszka
/s/ Aleksandar Rajkovic, M.D., Ph.DDirectorMarch 5, 2024
Aleksandar Rajkovic, M.D., Ph.D.
/s/ Christopher TwomeyDirectorMarch 5, 2024
Christopher Twomey
/s/ Kristiina Vuori, M.D., Ph.D.DirectorMarch 5, 2024
Kristiina Vuori, M.D., Ph.D.
/s/ Vincent Wong, J.D., M.B.A.DirectorMarch 5, 2024
Vincent Wong, J.D., M.B.A.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.